Ventyx Biosciences

NSQ:VTYX · US92332V1070

PharmaceuticalsSmall

360° View

Value32

Price/Sales—

Price/Earnings73

Price/Book9

Dividend Yield1

Growth90

Revenue Growth—

Profit Growth29

Capital Growth49

TSR 52w96

Safety76

Leverage64

Liquidity50

Refinancing64

Combined96

Sentiment23

Analyst Opinions1

Pro Holdings1

Opinion Changes2

Market Pulse51

Profile

CountryUSA

IndustryPharmaceuticals

SizeSmall

TypePrivate Company

ExchangeNASDAQGM

Founded2018

Employees76

Websiteventyxbio.com

ISINUS92332V1070

Last UpdateApr 2, 2026

Index & Theme

NeurologyRheumatologyObesityGastroenterologyCardiovascularImmunologyInflammationCentral Nervous SystemNeuroscienceBiopharmaBiotechnologyPharmaceuticalTherapeutics

Description

Ventyx Biosciences, Inc. (Ventyx Biosciences), a clinical-stage biopharmaceutical company, develops innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company’s expertise in medicinal chemistry,…

Analysis

Ventyx Biosciences's 360° View rank of 51 places it above its peer average — better than 51% of its true peers.

It's a growth standout (90) and on the expensive side (32). On safety it is very well financed (76), and the market shows skeptical sentiment (23). Taken together, its Combined rank of 96 reads as among the strongest overall.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Ventyx Biosciences with its peers

CalciMedica

NAQ:CALC

—

CountryUSA

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

EyePoint

NMQ:EYPT

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Fulcrum Therapeutics

NMQ:FULC

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

LB Pharmaceuticals

NMQ:LBRX

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Nektar

NAQ:NKTR

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Terns Pharmaceuticals

NSQ:TERN

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →